A look at the future-new BoNTs and delivery systems in development: What it could mean in the clinic

Ryuji Kaji

doi:10.1016/j.toxicon.2023.107264

A look at the future-new BoNTs and delivery systems in development: What it could mean in the clinic

Toxicon. 2023 Oct:234:107264. doi: 10.1016/j.toxicon.2023.107264. Epub 2023 Aug 30.

Author

Ryuji Kaji¹

Affiliation

¹ Tokushima University, Department of Clinical Neuroscience, 2-50-1 Kuramoto-cho, Tokushima, 770-8503, Japan. Electronic address: rkaji@tokushima-u.ac.jp.

PMID: 37657515
DOI: 10.1016/j.toxicon.2023.107264

Abstract

Despite the expanding clinical utility of botulinum neurotoxins, there remain problems to be solved for attaining the best outcome. The efficacy and safety need to be reconsidered for commercially available preparations all derived from subtype A1 or B1. Emerging new toxins include A2 or A6 subtypes or engineered toxins with less spread, more potency, longer durations of action, less antigenicity and better safety profile than currently used preparations. Non-toxic BoNTs with a few amino acid replacements of the light chain (LC) may have a role as a drug-delivery system if the toxicity is abolished entirely. At present, efficacy of these BoNTs in animal botulism was demonstrated.

Keywords: Botulinum neurotoxin; Drug delivery system; Hall strain; Less spread; Subtype A1; Subtype A2.

Publication types

Review